Trial tests new drug to help kids with rare hormone disorder

NCT ID NCT05128942

Terminated Disease control Sponsor: Spruce Biosciences Source: ClinicalTrials.gov ↗

Summary

This study tested a drug called tildacerfont in children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a rare genetic hormone disorder. The main goal was to see if the drug was safe and if it could help control the disease, potentially allowing for a reduction in the standard steroid medications these children must take. The trial was terminated and did not complete its planned testing phases.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Spruce Study Site

Sacramento, California, 95821, United States
Spruce Study Site

San Diego, California, 92123, United States
Spruce Study Site

Chicago, Illinois, 60611, United States
Spruce Study Site

Minneapolis, Minnesota, 55454, United States
Spruce Study Site

Buffalo, New York, 14203, United States
Spruce Study Site

Providence, Rhode Island, 02903, United States
Spruce Study Site

Columbia, South Carolina, 29203, United States
Spruce Study Site

Dallas, Texas, 75231, United States
Spruce Study Site

Edinburg, Texas, 78539, United States
Spruce Study Site

Fort Worth, Texas, 76104, United States
Spruce Study Site

Salt Lake City, Utah, 84113, United States
Spruce Study Site

Charlottesville, Virginia, 22903, United States
Spruce Study Site

Richmond, Virginia, 23284, United States

Conditions

Explore the condition pages connected to this study.

21-OHD CONGENITAL ADRENAL HYPERPLASIA